Mitsubishi Chemical Group Corporation Q3 FY2025 earnings call

• Overall Business Environment

  • Demand was broadly stable across the quarter, with mixed performance across regions and sectors: display-related demand in China remained strong driven by government subsidy policies; semiconductor-related demand saw gradual recovery supported by strong generative AI demand; automotive and food-related markets were soft.
  • Cumulative 9M cost reduction reached 41.1 billion yen, 87% of the full-year 47.0 billion yen target, making a major contribution to group profit.

• Operational Progress

  • The group's core chemical business saw large margin improvement centered on MMA and Basic Materials & Polymers, while Specialty Materials delivered improved volume performance.
  • Cancellation of the U.S. MMA monomer new plant project resulted in 16.8 billion yen total non-recurring loss (13.0 billion yen impairment of pre-development costs, 3.3 billion yen contract termination penalties), aligned with the group's commitment to strict investment discipline under its 2029 medium-term management plan.
  • Free cash flow totaled 131.8 billion yen cumulative 9M; net interest-bearing debt fell by 43.0 billion yen from the fiscal year-end, with net D/E ratio improving 0.05 points to 1.11.
  • Portfolio restructuring is ongoing: the group completed the sale of Kansai Thermochemical Co., Ltd. and continued divestment of non-core assets and policy-held shares.

• Strategic Alignment

  • Management continues to advance portfolio reform and profit improvement under the 2029 medium-term management plan, based on the three criteria for business selection and three principles of disciplined business operation.

1. Specialty Materials: 5% YoY revenue increase, 77% YoY core operating profit increase, with a 15.0 billion yen core operating profit gain YoY. It accounts for an approximate 24% share of total group revenue (based on aggregate segment growth contribution).
2. MMA & Derivatives: 20% YoY revenue increase, with a 30.0 billion yen core operating profit gain YoY. It accounts for an approximate 14% share of total group revenue.
3. Basic Materials & Polymers: 6% YoY revenue decrease, with a 2.8 billion yen reduction in net operating deficit YoY. The Materials & Polymers sub-segment delivered double-digit positive core operating profit despite planned annual turnaround at the Ibaraki facility, while the Carbon sub-segment recorded a 21.3 billion yen core operating deficit. It accounts for an approximate 28% share of total group revenue.
4. Pharma: 3% YoY revenue increase, 2% YoY core operating profit decrease (a 0.9 billion yen profit decline YoY). It accounts for an approximate 18% share of total group revenue.
5. Industrial Gases: 5% YoY revenue increase, 12% YoY core operating profit increase, with a 15.0 billion yen core operating profit gain YoY. It accounts for an approximate 16% share of total group revenue.

Aggregate group cumulative 9M revenue: 333.15 billion yen (3.3315 trillion yen), 3% YoY increase. Aggregate group cumulative 9M core operating profit: 247.2 billion yen (247.2 billion yen), 34% YoY increase.

• Full-year core operating profit guidance is maintained at 290.0 billion yen. Cumulative 9M core operating profit reached 85% of the full-year target, but Q4 profit is expected to decline due to seasonal factors in Specialty Materials and Pharma, as well as projected margin compression for MMA monomer.
• Full-year parent net profit guidance is maintained at 52.0 billion yen. While 9M performance is ahead of plan due to Q3 foreign exchange gains, projected non-recurring losses from additional structural reform projects in Q4 offset this over-performance.
• Full-year dividend guidance is maintained at 32 yen per share (16 yen year-end dividend).
• For next fiscal year, management expects the largest profit growth rate improvement to come from Basic Materials & Polymers, driven by the elimination of the Carbon sub-segment's deficit. Specialty Materials is also projected to deliver growth, with the successful turnaround of Advanced Composites & Shapes (carbon fiber composites) remaining a key priority.
• Carbon sub-segment (coke business): management targets a return to net profitability by the first half of next fiscal year at the latest, no later than the end of next calendar year.

• Commodity chemical market volatility: MMA monomer market prices in Asia fell sharply after other producers restarted idled capacity, with Chinese competitors repeating the pattern of raising output when prices rise, pushing prices back down, creating continued market uncertainty.
• Structural headwinds: non-polymer petrochemical derivative products (14BG, acrylic acid, ethylene oxide) face ongoing competition from imported finished goods, leading to continued weak profitability.
• Carbon fiber business headwinds: intense competition in the high-volume, low-margin large tow carbon fiber market (for wind power applications), plus declining sales volume of higher-margin pressure vessel applications, leading to widening deficits; upstream/downstream capacity imbalance is a core challenge.
• Pharma sector headwinds: Japan's new selective medical care system has caused larger-than-expected volume declines for long-listed off-patent drugs, partially offset by strong sales growth of new products including Mounjaro.
• EV value chain headwinds: EV electrolyte is facing intense pricing competition, and demand has softened after a period of overinflated market expectations, with weak conditions expected to persist for the foreseeable future.

Q: After canceling the U.S. MMA project, do you still have confidence in the MMA business and are you waiting for customer commitments that risk missing investment opportunities? / A: Management remains convinced the group is the best owner for the MMA business, and will maintain its market presence, with all relevant intangible expertise retained despite the write-down. Securing long-term price and volume commitments from key customers for large commodity projects is extremely difficult, and the group will not deviate from strict investment discipline: the project did not meet required ROIC hurdles, so cancellation was appropriate. The group will continue to evaluate future U.S. investment opportunities as market conditions evolve.

Q: How is the widening deficit at Advanced Composites & Shapes being addressed, and when will capacity optimization improve profitability? / A: The core problem is upstream/downstream capacity imbalance, so the first priority is cutting excess capacity this fiscal year to reduce fixed costs and align upstream production with downstream demand. The business will shift its portfolio away from large tow carbon fiber (commodity wind power applications) to higher-value, higher-grade products for mobility and other targeted end markets, and targets a profit recovery in FY2025. Management declined to share a specific timeline for when cost cuts will deliver full profit improvement.

Q: What is your outlook for the Carbon (coke) business return to profitability, and what is the strategy for the petrochemical business? / A: Coke spread turned positive starting in December as coking coal prices fell, and high-cost legacy inventory is nearly depleted. Management targets return to net profitability by the end of the first half of next fiscal year, with a possible slip to the second half, but commits to achieving black ink no later than calendar year-end. The business is shifting from open market trading to tolling (fixed processing fee) contracts, which is progressing in customer negotiations. For petrochemicals, crackers are running at 90% utilization (vs 70% domestic industry average), and polyolefins are performing well, but non-polymer derivatives are struggling. The group is evaluating capacity cuts to reposition the business to eliminate ongoing structural losses, and targets consistent profitability (not Specialty-level ROIC) within 3 years, barring major operational disruptions.

Q: What is the management's priority if portfolio changes alter gross medium-term numerical targets? / A: Management prioritizes hitting an 8% ROIC target over gross core operating profit numerical goals. If the portfolio composition changes (such as the potential sale of Tanabe Mitsubishi Pharma), the absolute ROIC target may be adjusted slightly, but ROIC remains the primary performance metric for evaluating business structure changes.